Rentschler Invests in New Stainless-Steel Bioreactors - - BioPharm International

ADVERTISEMENT

Rentschler Invests in New Stainless-Steel Bioreactors



Rentschler Biotechnologie GmbH, a CMO for the development and production of biopharmaceuticals, reported the investment of €24 million (approximately $32 million) to build a twin system with two 3000-L stainless-steel bioreactors mainly targeting market supply at the company’s site in Laupheim, Germany. The twin system should be operational in early 2017.

The twin system is designed for running two main bioreactors in parallel with one shared downstream processing unit, thus providing higher throughput while reducing incremental labor costs involved. It will be integrated into the existing 3000-L GMP line and will more than double the production capacities for cell culture-derived proteins. The twin system will allow Rentschler to run cell-culture processes in fed-batch mode with a high output in a single suite.

Source:Rentschler Biotechnologie GmbH

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines

Click here